Celcuity (CELC) Cash from Financing Activities (2016 - 2025)
Celcuity (CELC) posted Cash from Financing Activities of $24.4 million for Q4 2025, down 92.6% on a QoQ basis from $330.3 million in Q3 2025, and up 19770.73% year-over-year from N/an in Q4 2024.
Celcuity (CELC) Cash from Financing Activities (2016 - 2025) Analysis & Trends
Celcuity's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $24.4 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 19770.73% year-over-year to $24.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $360.6 million (up 160.54% YoY) and the FY2025 annual result came in at $360.6 million, up 160.54% from the prior year.
- Cash from Financing Activities was $24.4 million for Q4 2025 at Celcuity, down from $330.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $330.3 million in Q3 2025 and bottomed at -$108166.0 in Q3 2022.
- A 5-year average of $38.9 million and a median of $3.2 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 1797799.65% — and 2022, when it tumbled 100.51%.
- Celcuity's Cash from Financing Activities stood at $53510.0 in 2021, then soared by 225188.94% to $120.6 million in 2022, then plunged by 46.37% to $64.7 million in 2023, then plunged by 99.81% to $123000.0 in 2024, then jumped by 19770.73% to $24.4 million in 2025.
- Business Quant data shows CELC's Cash from Financing Activities at $24.4 million in Q4 2025, $330.3 million in Q3 2025, and $232000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Celcuity | 4.13 Bn | 4.13 Bn | - | 24.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.44 Mn |
| Dec 31, 2025 | 24.44 Mn |
| Sep 30, 2025 | 330.33 Mn |
| Sep 30, 2025 | 330.33 Mn |
| Jun 30, 2025 | 232,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Mar 31, 2025 | 5.55 Mn |
| Mar 31, 2025 | 5.55 Mn |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 803,000.00 |
| Sep 30, 2024 | 803,000.00 |
| Jun 30, 2024 | 123.38 Mn |
| Jun 30, 2024 | 123.38 Mn |
| Mar 31, 2024 | 14.08 Mn |
| Mar 31, 2024 | 14.08 Mn |
| Dec 31, 2023 | 64.66 Mn |
| Dec 31, 2023 | 64.66 Mn |
| Sep 30, 2023 | 15,244.00 |
| Sep 30, 2023 | 15,244.00 |